Daewoong Pharmaceutical Future Growth
Future criteria checks 1/6
Daewoong Pharmaceutical is forecast to grow earnings and revenue by 5.1% and 2.3% per annum respectively. EPS is expected to grow by 5% per annum. Return on equity is forecast to be 12.7% in 3 years.
Key information
5.1%
Earnings growth rate
5.0%
EPS growth rate
Pharmaceuticals earnings growth | 36.9% |
Revenue growth rate | 2.3% |
Future return on equity | 12.7% |
Analyst coverage | Good |
Last updated | 04 Jul 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,492,484 | 119,311 | 104,523 | 194,000 | 3 |
12/31/2025 | 1,372,859 | 116,889 | 99,418 | 159,733 | 6 |
12/31/2024 | 1,289,346 | 78,113 | 96,676 | 107,000 | 4 |
3/31/2024 | 1,388,699 | 114,474 | -53,452 | 126,812 | N/A |
12/31/2023 | 1,375,329 | 121,739 | -19,618 | 136,009 | N/A |
9/30/2023 | 1,341,290 | 46,381 | 43,333 | 170,054 | N/A |
6/30/2023 | 1,332,284 | 51,305 | 19,019 | 136,131 | N/A |
3/31/2023 | 1,304,151 | 44,030 | 6,342 | 118,959 | N/A |
12/31/2022 | 1,280,092 | 42,240 | 6,162 | 118,215 | N/A |
9/30/2022 | 1,255,325 | 82,107 | -13,414 | 87,701 | N/A |
6/30/2022 | 1,214,081 | 72,576 | -65 | 78,402 | N/A |
3/31/2022 | 1,181,714 | 61,231 | -25,785 | 65,359 | N/A |
12/31/2021 | 1,152,976 | 24,506 | -34,727 | 39,994 | N/A |
9/30/2021 | 1,117,201 | 11,539 | -21,549 | 45,667 | N/A |
6/30/2021 | 1,103,387 | 2,971 | -8,568 | 68,925 | N/A |
3/31/2021 | 1,067,635 | -11,030 | 20,341 | 81,301 | N/A |
12/31/2020 | 1,055,424 | 12,753 | 43,714 | 100,981 | N/A |
9/30/2020 | 1,075,831 | -1,657 | -2,683 | 53,237 | N/A |
6/30/2020 | 1,068,433 | -2,480 | 2,987 | 49,749 | N/A |
3/31/2020 | 1,107,158 | 16,828 | 13,031 | 57,437 | N/A |
12/31/2019 | 1,113,426 | 22,006 | 8,989 | 57,600 | N/A |
9/30/2019 | 1,098,180 | -8,021 | 81,272 | 126,212 | N/A |
6/30/2019 | 1,086,724 | -6,314 | 33,847 | 97,101 | N/A |
3/31/2019 | 1,055,675 | -12,079 | 2,178 | 66,602 | N/A |
12/31/2018 | 1,031,427 | -15,152 | -8,863 | 47,500 | N/A |
9/30/2018 | 995,896 | 19,610 | -8,088 | 49,029 | N/A |
6/30/2018 | 990,152 | 25,296 | -24,103 | 48,832 | N/A |
3/31/2018 | 973,800 | 31,077 | 3,406 | 82,155 | N/A |
12/31/2017 | 960,307 | 31,581 | N/A | 103,938 | N/A |
9/30/2017 | 959,672 | 39,318 | N/A | 60,986 | N/A |
6/30/2017 | 927,950 | 34,453 | N/A | 49,717 | N/A |
3/31/2017 | 898,632 | 27,433 | N/A | 21,664 | N/A |
12/31/2016 | 883,920 | 26,970 | N/A | 15,377 | N/A |
9/30/2016 | 862,689 | 19,704 | N/A | 19,176 | N/A |
6/30/2016 | 869,026 | 26,021 | N/A | 43,180 | N/A |
3/31/2016 | 857,252 | 34,413 | N/A | 44,974 | N/A |
12/31/2015 | 839,686 | 42,930 | N/A | 35,888 | N/A |
9/30/2015 | 812,337 | 44,657 | N/A | 21,960 | N/A |
6/30/2015 | 778,975 | 28,576 | N/A | 26,489 | N/A |
3/31/2015 | 758,475 | 30,555 | N/A | 36,310 | N/A |
12/31/2014 | 735,889 | 31,544 | N/A | 25,945 | N/A |
9/30/2014 | 734,716 | 31,176 | N/A | 42,933 | N/A |
6/30/2014 | 714,185 | 56,700 | N/A | 21,313 | N/A |
3/31/2014 | 690,275 | 58,808 | N/A | 24,093 | N/A |
12/31/2013 | 682,508 | 58,400 | N/A | 54,157 | N/A |
9/30/2013 | 639,940 | 60,137 | N/A | 67,406 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A069620's forecast earnings growth (5.1% per year) is above the savings rate (2.5%).
Earnings vs Market: A069620's earnings (5.1% per year) are forecast to grow slower than the KR market (29.5% per year).
High Growth Earnings: A069620's earnings are forecast to grow, but not significantly.
Revenue vs Market: A069620's revenue (2.3% per year) is forecast to grow slower than the KR market (10.4% per year).
High Growth Revenue: A069620's revenue (2.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A069620's Return on Equity is forecast to be low in 3 years time (12.7%).